在我的职位上，我领导血液学肿瘤学R&D, with responsibilities spanning from early discoveries and target identification, 到首次人体临床研究, 到后期试验和药物批准.

I am a clinician-scientist and have spent more than 25 years caring for patients with lymphoma. 加入澳门葡京网赌游戏之前, I was at Memorial Sloan Kettering Cancer Center (MSKCC) where I served as the Chief of the Lymphoma Service, in addition to leading a laboratory focused on drug development for patients with lymphoid malignancies. Our lab was focused on accelerating the translation of scientific discoveries into novel treatment strategies to improve the cure rate and survival of patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). 在MSKCC之前, I worked for 20 years at University of Texas MD安德森癌症中心 (MDACC) where I directed clinical and translational research in the Department of Lymphoma and Myeloma.

 

在我的学术生涯中, I lead numerous clinical trials that advanced the field and resulted in the U.S. Food and Drug Administration approval of two novel agents for patients with Hodgkin's lymphoma, including the first targeted drug for the treatment of Hodgkin lymphoma in more than three decades, and the approval of the first immune checkpoint inhibitor for lymphoma. 在同一时间, our groups’ efforts at MDACC and MSKCC resulted in 11 new approved indications for the treatment of patients with different types of lymphoid malignancies.

我在同行评议的期刊上发表了300多篇论文, served as the principal investigator of more than 60 clinical trials, 包括国家和国际多中心研究, and led two independent National Cancer Institute–funded Specialized Programs of Research Excellence at MDACC and MSKCC that focused on novel drug development for patients with lymphoma. 我还领导过白血病 & Lymphoma Society-sponsored Specialized Center of Research program focusing on developing a second-generation CAR(嵌合抗原受体)t细胞疗法 针对血癌患者. I am a past member of the Scientific Advisory Board of the Lymphoma Research Foundation.

在获得医学学位后 大马士革大学 叙利亚医学院, I completed residencies in pathology at the College of Medicine and Life Sciences at the University of Toledo in Ohio, 纽约州立大学下州立医学院内科博士, in New York, 并获得MSKCC血液学/肿瘤学奖学金.

 

We’ve made so much progress in treating blood cancers over the last two decades, 并且正在进入一个令人兴奋的研究新阶段. 作为临床医生, I have seen the impact our progress has had on the lives of patients with blood cancers. I am proud to bring my background as a researcher and haematologist to the AstraZeneca scientific community to develop a new generation of medicines that will transform lives of people with blood cancers.

Anas Younes 高级副总裁, 血液学(早期和晚期)肿瘤学全球主管&D、澳门葡京网赌游戏

电流的作用

高级副总裁, 血液学(早期和晚期)肿瘤学全球主管&D、澳门葡京网赌游戏

2013-2019

Served as Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center, and was a special advisor to the Chief of Medicine for Research and the Steven A. 2019-2020年格林伯格淋巴瘤研究主席

1992-2013

MD安德森癌症中心, 担任医学教授近十年, served as the Director of Clinical and Translational Research in the Department of Lymphoma and Myeloma

2013

获德国科隆霍奇金淋巴瘤奖

特色的出版物

淋巴瘤新出现的表观遗传调节疗法

Sermer D, Pasqualucci L, Wendel HG, Melnick A， Younes A. Nat Rev Clin Oncol. 2019年8月,16 (8):494 - 507. http://www.nature.com/articles/s41571-019-0190-8

Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study

Younes A, Brody J, Carpio C, Lopez-Guillermo一, 本耶胡达D, Ferhanoglu B, Nagler A, Ozcan M, Avivi I, Bosch F, 卡巴列罗Barrigón MD, Hellmann A, Kuss B, Ma DDF, Demirkan F, Yağci M, Horowitz NA, Marlton P, Cordoba R, Wrobel T, Buglio D, Streit M, Hodkinson英国石油公司, Schaffer M, Alvarez J, Ceulemans R, Balasubramanian年代, de Jong J, Wang SS, Fourneau N, Jurczak W. 柳叶刀Haematol. 2019年2月,6 (2):e67-e78. http://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(18)30217-5/fulltext

 

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma

conors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A， Younes A, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, 坎宁安D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J; ECHELON-1 Study Group. [英]医学. 2018年1月25日;378(4):331-344. http://www.nejm.org/doi/10.1056/NEJMoa1708984

国际 Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)

Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, Seymour JF, Kelly K, Gribben J, Pfreunschuh米, Morschhauser F, Schoder H, Zelenetz AD, Rademaker J, Advani R, Valente N, Fortpied C, Witzig TE, Sehn LH, Engert A, Fisher RI, Zinzani PL, Federico M, Hutchings M, Bollard C, Trneny M, Elsayed YA, Tobinai K, Abramson JS, Fowler N, Goy A, Smith M, Ansell S, Kuruvilla J, Dreyling M, Thieblemont C, Little RF, Aurer I, Van Oers MHJ, Takeshita K, Gopal A, Rule S, de Vos S, Kloos I, Kaminski MS, Meignan M, Schwartz LH, Leonard JP, Schuster SJ, Seshan VE. Ann Oncol. 2017年7月1日;28(7):1436-1447. http://www.annalsofoncology.org/article/S0923-7534(19)32246-X/fulltext

 

Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, 美国临床肿瘤学会, 和美国病理学家学会

Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, Tsimberidou我, Vnencak-Jones CL, Wolff DJ, Younes A, Nikiforova MN.J Mol Diagn. 2017年1月,19 (1):4-23. http://www.jmdjournal.org/article/S1525-1578(16)30223-9/fulltext

Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma

Chen R, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Connors JM, Engert A, Larsen EK, Huebner D, Fong A, Younes A. Blood. 2016年9月22日;128(12):1562-6. http://ashpublications.org/blood/article/128/12/1562/73112/Five-year-survival-and-durability-results-of

 

Safety, 耐受性, CUDC-907的初步活性, 一个first-in-class, oral, HDAC和PI3K双重抑制剂, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, 剂量递增, 一期试验

Younes A, Berdeja JG, Patel MR, Flinn I, Gerecitano摩根富林明, Neelapu SS, Kelly KR, Copeland AR, Akins A, Clancy MS, Gong L, Wang J, Ma A, Viner JL, Oki Y. 《澳门葡京网赌游戏》杂志. 2016年5月,17(5):622 - 31所示. http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00584-7/fulltext

 

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, 单臂2期试验.

Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, Armand P, Fanale M, Ratanatharathorn V, Kuruvilla J, Cohen JB, Collins G, Savage KJ, Trneny M, Kato K, Farsaci B, Parker SM, Rodig S, Roemer MG, Ligon AH, Engert A. 《澳门葡京网赌游戏》杂志. 2016年9月,17 (9):1283 - 94. http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30167-X/fulltext 

 

Veeva ID: Z4-60100
筹备日期:2023年11月